Biopharma companies raised $28.74 billion across the first half of 2025, representing a 59% decline compared to the same period in 2024 but aligning with prior years such as 2022 and 2023. Monthly financing totals rose through April to June, indicating recovering momentum. Notable funding rounds in June included Insmed, Cidara Therapeutics, and Cogent Biosciences. Digital health and AI-related investments remain strong components of capital flow in the sector as startups increasingly attract investor interest.